Movement Alert|Twist Bioscience Corp Intraday Decline 5.01%, post-earnings growth reset and analyst target cuts weigh on sentiment

Market Focus11-20 22:38

On November 20, Twist Bioscience Corp fell 5.01% in Regular Trading, trading at $102.57 per share, with turnover of $22.4468 million.

The move came as the market continued to digest the company’s latest quarterly results, management’s indication of slower AI drug discovery-related growth, and several post-earnings target-price cuts that pressured near-term sentiment.

Background context shows Twist Bioscience Corp reported fiscal fourth-quarter revenue of $126.6 million and a loss of $0.32 per share, both better than consensus. Fiscal first-quarter revenue guidance of $130 million to $132 million and full-year revenue guidance of $550 million to $560 million were also slightly above expectations. Even so, management indicated slower growth in AI drug discovery-related business, while UBS cut its target price to $120, Jefferies lowered its target to $125, and Guggenheim reduced its target to $150, although Piper Sandler later raised its target to $140, underscoring continued analyst divergence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment